Synopsis Testosterone prescriptions have increased substantially in men with metabolic syndrome within the last decades. However, the risk/benefit ratio of such treatment is highly controversial, especially in view of conflicting data on cardiovascular outcomes. The present study aims to test the inflammatory hypothesis of testosterone deficiency in metabolic syndrome. This week’s “ MED FACT ” discusses a randomized control trial from British Journal of Surgery, “ IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial ”. Authors: F.
Ebrahimi et. al. Key Takeaways Anti-inflammatory treatment with an antagonist of IL-1 led to an increase in testosterone levels in obese men with testosterone deficiency. Objective: The present study aims to test the inflammatory hypothesis of testosterone deficiency in metabolic syndrome. Study Type:…
